Cargando…

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia

OBJECTIVES: Cefotaxime-resistant Enterobacteriaceae (CE) infections are intractable, with limited treatment options. Though carbapenems are frequently prescribed for CE infections, the emergence of carbapenem-resistant Enterobacteriaceae is of huge concern. Flomoxef is effective against CE in vitro,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chen-Hsiang, Chen, I-Ling, Li, Chia-Chin, Chien, Chun-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826091/ https://www.ncbi.nlm.nih.gov/pubmed/29503575 http://dx.doi.org/10.2147/IDR.S146923

Ejemplares similares

Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

The rapid detection of cefotaxime-resistant Enterobacteriaceae by HPLC
por: Robinson, Andrew M, et al.
Publicado: (2016)

2266. Management of Ertapenem-Resistant, Meropenem-Susceptible Enterobacteriaceae
por: Srinivas, Pavithra, et al.
Publicado: (2019)

Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
por: Noguchi, Taro, et al.
Publicado: (2017)

Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniae in patients on maintenance hemodialysis
por: Yang, Chih-Chao, et al.
Publicado: (2012)

Screening for Carbapenemases in Ertapenem-Resistant Enterobacteriaceae Collected at a Tunisian Hospital Between 2014 and 2018
por: Kollenda, Hans, et al.
Publicado: (2019)

Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan
por: Lee, Sai-Cheong, et al.
Publicado: (2007)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
por: Chou, Andrew, et al.
Publicado: (2018)

Ertapenem Resistance of Escherichia coli
por: Lartigue, Marie-Frédérique, et al.
Publicado: (2007)

Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study
por: Teo, Jocelyn, et al.
Publicado: (2012)

Successful Treatment of High-Level Aminoglycoside-Resistant Enterococcus faecalis Bacteremia in a Preterm Infant with Ampicillin and Cefotaxime
por: Tam, Jennifer, et al.
Publicado: (2018)

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
por: Darlow, Christopher A., et al.
Publicado: (2022)

Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia
por: Sakoulas, George, et al.
Publicado: (2016)

Impact of teicoplanin maintenance dose and MIC values on the clinical outcomes of patients treated for methicillin-resistant Staphylococcus aureus bacteremia
por: Tsai, Ching-Yen, et al.
Publicado: (2018)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

Evaluating the Impact of Long-Term Outpatient Ertapenem (ETP) vs. Ceftriaxone (CTX) on Clinical Success and Development of Resistance for Documented Enterobacteriaceae Infections
por: Carver, Peggy, et al.
Publicado: (2017)

Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation
por: Sanclemente, Gemma, et al.
Publicado: (2019)

518. Comparing the Mortality of Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Seo, Hyeonji, et al.
Publicado: (2019)

Timing of Initiating Glycopeptide Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical Outcome
por: Lee, Chen-Hsiang, et al.
Publicado: (2013)

CEFOTAXIME IN THE TREATMENT OF BACTERIAL MENINGITIS
por: Asmar, Basim I, et al.
Publicado: (1984)

217. Combination Salvage Therapy with Cefazolin Plus Ertapenem for Refractory Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Rose Ulloa, Erlinda, et al.
Publicado: (2019)

Ertapenem-Induced Thrombocytosis
por: Docobo, Ramon A, et al.
Publicado: (2017)

1885. Cost-Effectiveness of Ceftazidime–Avibactam Compared With Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
por: Sfeir, Maroun, et al.
Publicado: (2018)

No Resistance to Penicillin, Cefuroxime, Cefotaxime, or Vancomycin in Pneumococcal Pneumonia
por: Yayan, Josef, et al.
Publicado: (2015)

Identification and Characterization of Cefotaxime Resistant Bacteria in Beef Cattle
por: Mir, Raies A., et al.
Publicado: (2016)

Persistent Methicillin-Susceptible Bacteremia Rapidly Cleared with Cefazolin and Ertapenem Combination Therapy in a Patient with COVID-19
por: Ilges, Dan, et al.
Publicado: (2022)

191. Appropriateness of Empiric Antibiotics for Enterobacteriaceae Bacteremia
por: Smith, Brandon J, et al.
Publicado: (2019)

2447. Ertapenem and Faropenem for the Treatment of Drug-Resistant Tuberculosis
por: Satta, Giovanni, et al.
Publicado: (2018)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

Factors Associated with Mortality in Carbapenem-Resistant Enterobacteriaceae Bacteremia: Focus on Antibiotic Therapy
por: Pillinger, Kelly E, et al.
Publicado: (2017)

Treatment of sepsis: What is the antibiotic choice in bacteremia due to carbapenem resistant Enterobacteriaceae?
por: Alhashem, Fatema, et al.
Publicado: (2017)

Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae
por: Bang, Ji Hwan, et al.
Publicado: (2013)

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022)

Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review
por: Zequinão, Tiago, et al.
Publicado: (2020)

Diabetes does not affect outcome in patients with Enterobacteriaceae bacteremia
por: Peralta, Galo, et al.
Publicado: (2009)

Efficacy and Cost Comparison of Ertapenem as Outpatient Parenteral Antimicrobial Therapy in Acute Pyelonephritis due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae
por: Ramasubramanian, V., et al.
Publicado: (2018)

Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections
por: Wong, Carrie P., et al.
Publicado: (2021)

Population pharmacokinetics of cefotaxime in intensive care patients
por: Swartling, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l30gcn9n2dh6f0l2vns42krugo